JP4662634B2 - 胃透過性の低い水性腸溶性被覆組成物 - Google Patents

胃透過性の低い水性腸溶性被覆組成物 Download PDF

Info

Publication number
JP4662634B2
JP4662634B2 JP2000571896A JP2000571896A JP4662634B2 JP 4662634 B2 JP4662634 B2 JP 4662634B2 JP 2000571896 A JP2000571896 A JP 2000571896A JP 2000571896 A JP2000571896 A JP 2000571896A JP 4662634 B2 JP4662634 B2 JP 4662634B2
Authority
JP
Japan
Prior art keywords
weight
water
composition
enteric
flake material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000571896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002525313A (ja
JP2002525313A5 (enExample
Inventor
ウー，スティーブン，ホン−ウェイ
ウェイン アダムス，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastman Chemical Co
Original Assignee
Eastman Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Chemical Co filed Critical Eastman Chemical Co
Publication of JP2002525313A publication Critical patent/JP2002525313A/ja
Publication of JP2002525313A5 publication Critical patent/JP2002525313A5/ja
Application granted granted Critical
Publication of JP4662634B2 publication Critical patent/JP4662634B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
JP2000571896A 1998-09-29 1999-09-13 胃透過性の低い水性腸溶性被覆組成物 Expired - Fee Related JP4662634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/162,282 1998-09-29
US09/162,282 US6139875A (en) 1998-09-29 1998-09-29 Aqueous enteric coating composition and low gastric permeability enteric coating
PCT/US1999/021072 WO2000018376A1 (en) 1998-09-29 1999-09-13 Aqueous enteric coating composition with low gastric permeability

Publications (3)

Publication Number Publication Date
JP2002525313A JP2002525313A (ja) 2002-08-13
JP2002525313A5 JP2002525313A5 (enExample) 2006-11-24
JP4662634B2 true JP4662634B2 (ja) 2011-03-30

Family

ID=22584979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000571896A Expired - Fee Related JP4662634B2 (ja) 1998-09-29 1999-09-13 胃透過性の低い水性腸溶性被覆組成物

Country Status (5)

Country Link
US (1) US6139875A (enExample)
EP (1) EP1117385B1 (enExample)
JP (1) JP4662634B2 (enExample)
DE (1) DE69928555T2 (enExample)
WO (1) WO2000018376A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
KR100461566B1 (ko) * 2001-11-15 2004-12-14 삼성정밀화학 주식회사 수계 분산 히드록시프로필메틸 셀룰로오스 프탈레이트나노입자의 제조방법
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
KR100511086B1 (ko) * 2003-09-17 2005-08-30 삼성정밀화학 주식회사 장용성의 수계 분산 히드록시프로필 메틸셀룰로오스프탈레이트 나노입자의 제조방법
KR20050080626A (ko) * 2004-02-10 2005-08-17 삼성정밀화학 주식회사 수계분산 히드록시프로필 메틸셀룰로오스 프탈레이트나노입자 조성물의 제조방법
PE20060003A1 (es) 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
WO2007016563A2 (en) * 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
ES2567595T3 (es) * 2005-10-12 2016-04-25 Opko Renal, Llc Métodos y artículos para tratar la insuficiencia y la deficiencia de 25-hidroxivitamina D
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
DK1993559T3 (en) 2006-02-03 2016-10-03 Opko Renal Llc Treatment of vitamin D deficiency and MALFUNCTION with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
US8968799B2 (en) * 2006-09-01 2015-03-03 Rise-N-Shine L.L.C. Time delayed release mechanism for energizing composition and method of use
FI3225243T3 (fi) 2007-04-25 2025-10-13 Opko Renal Llc Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
WO2009047644A2 (en) * 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2148685A4 (en) * 2007-04-25 2010-07-28 Cytochroma Inc METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
DK2481400T3 (da) 2007-04-25 2014-09-29 Opko Ip Holdings Ii Inc Orale præparater med kontrolleret frigivelse omfattende en vitamin D-forbindelse og en voksagtig bærer
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
JP2012518635A (ja) 2009-02-24 2012-08-16 リター ファーマシューティカルズ インコーポレイテッド プレバイオティック製剤および使用方法
WO2011032169A2 (en) * 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
EP3636280B1 (en) 2010-03-29 2025-05-14 EirGen Pharma Ltd. Methods and compositions for reducing parathyroid levels
WO2014093988A2 (en) 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
WO2016172191A1 (en) 2015-04-20 2016-10-27 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting cnksr1
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20160331689A1 (en) 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
JP6895961B2 (ja) 2015-11-03 2021-06-30 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 食物アレルギーの処置および／または防止のための治療用微生物叢
MX395229B (es) 2016-03-28 2025-03-21 Opko Ireland Global Holdings Ltd Métodos de tratamiento con vitamina d.
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
AU2018365877A1 (en) 2017-11-10 2020-05-28 Nutrition & Biosciences USA 4, Inc. Unique morphological polysaccharide
CN111936570A (zh) 2017-12-14 2020-11-13 杜邦工业生物科学美国有限责任公司 α-1，3-葡聚糖接枝共聚物
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
FR3083545A1 (fr) 2018-07-04 2020-01-10 Institut National De La Recherche Agronomique Utilisation d'une souche de roseburia intestinalis pour la prevention et le traitement de l'inflammation de l'intestin
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020086935A1 (en) 2018-10-25 2020-04-30 Dupont Industrial Biosciences Usa, Llc Alpha-1,3-glucan graft copolymers
CA3116415A1 (en) 2018-11-05 2020-05-14 MarvelBiome, Inc. Microbial compositions comprising ellagitannin and methods of use
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
CA3159763A1 (en) 2019-11-06 2021-05-14 Nutrition & Biosciences USA 4, Inc. Highly crystalline alpha-1,3-glucan
US11733011B2 (en) * 2020-11-24 2023-08-22 Raytheon Company Steering system with power take-off from actuators
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPH07552B2 (ja) * 1987-11-06 1995-01-11 田辺製薬株式会社 持効性製剤
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5104922A (en) * 1990-10-22 1992-04-14 E. I. Du Pont De Nemours And Company Stable aqueous aluminum flake dispersion
JP2925346B2 (ja) * 1991-03-18 1999-07-28 田辺製薬株式会社 腸溶性製剤およびその製法
WO1995016451A1 (fr) * 1992-06-22 1995-06-22 Franck Arno Gouchet Comprimes a liberation controlee de 4-asa
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5612397A (en) * 1994-12-19 1997-03-18 Rohm And Haas Company Composition having wet state clarity
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
JPH08333240A (ja) * 1995-06-02 1996-12-17 Shin Etsu Chem Co Ltd 粉末またはペレット状ワックスを用いる無溶媒腸溶性コーティング剤で被覆した腸溶性製剤
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
US5756008A (en) * 1996-08-14 1998-05-26 E. I. Du Pont De Nemours And Company Water cleanable silver composition

Also Published As

Publication number Publication date
JP2002525313A (ja) 2002-08-13
DE69928555T2 (de) 2006-03-30
EP1117385B1 (en) 2005-11-23
DE69928555D1 (de) 2005-12-29
US6139875A (en) 2000-10-31
WO2000018376A1 (en) 2000-04-06
EP1117385A1 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
JP4662634B2 (ja) 胃透過性の低い水性腸溶性被覆組成物
US6974591B2 (en) Method for producing a controlled-release preparation
US5225202A (en) Enteric coated pharmaceutical compositions
CA2903375C (en) Delayed release film coatings containing calcium silicate and substrates coated therewith
RU2528095C2 (ru) Системы пленочного покрытия для препаратов с немедленным высвобождением, создающие усиленный барьер от влаги, и субстраты с таким покрытием
US6096340A (en) Omeprazole formulation
JP4641075B2 (ja) ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法
BRPI0721654A2 (pt) formas de dosagem sàlida compreendendo um revestimento entÉrico com liberaÇço acelerada do fÁrmaco
WO2005044240A2 (en) Stable lansoprazole formulation
PT93029A (pt) Processo para a preparacao de uma composicao contendo acido 5-(2,5- dimetilfenoxi)-2,2-dimetil-pentanoico (gemfibrozilo) de libertacao modificada
JP2782691B2 (ja) 腸溶製剤の安定化
EP1748764B1 (en) An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production
WO2010136219A1 (en) Enteric coating
JP2007517038A (ja) 薬学的組成物
JPS5942325A (ja) コ−テイング用組成物及びコ−テイング製剤
JPH02240016A (ja) 水分散性ジエムフイブロジル組成物
JP2002316928A (ja) コーティング錠及びコーティング錠のはがれを防止する方法
JP2008524257A (ja) 粘着防止剤と共に微粒化した腸溶性ポリマーを含有する腸溶性フィルムコーティング組成物
GB2353215A (en) Aqueous enteric coating formulation, with buffer (eg ammonium hydrogen carbonate) which solubilises enteric polymer yet decomposes on drying of the coating
WO2010037849A1 (en) Duloxetine enteric pellets
BR112020020783A2 (pt) revestimentos acidificante e substratos resistentes à desintegração revestidos com os mesmos
WO2008015530A2 (en) Stable solid oral formulation of pantoprazole
WO2013045961A1 (en) Coating composition
JPH0559098B2 (enExample)
TR2023014802T2 (tr) Mesalazi̇n enteri̇k tablet formülasyon bi̇leşi̇mi̇

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100519

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110104

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140114

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees